Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose study of JBP-TPOXX in Japanese healthy subjects
jRCT2031230327Phase 1Active, not recruiting
- Sponsor
- Japan Biotechno Pharma
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tecovirimat in mpox, smallpox, cowpox and 1 more, sponsored by Japan Biotechno Pharma. Primary endpoint: Safety and tolerability. Started Jul 2023; status: active, not recruiting.
02
Drugs
tecovirimat
03
Conditions
mpoxsmallpoxcowpoxvaccinia virus infection
Beyond the preview
Go deeper on jRCT2031230327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230327.